Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Novartis
- 30 Jun 2017 Planned number of patients changed from 60 to 61.
- 12 May 2017 Planned number of patients changed from 30 to 60.
- 12 May 2017 Planned End Date changed from 21 Mar 2020 to 4 Sep 2023.